H. Lundbeck A/S
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- H. Lundbeck A/S is a Denmark-based international pharmaceutical company specializing exclusively in the research, development, manufacture, and commercialization of pharmaceuticals for the treatment of brain diseases. Its core product portfolio addresses psychiatric and neurological disorders including depression, anxiety, schizophrenia, bipolar disorder, epilepsy, Huntington's disease, Alzheimer's disease, Parkinson's disease, alcohol dependence, and migraine. Key products include Cipralex (escitalopram) for depression and anxiety; Ebixa (memantine) for Alzheimer's; Azilect (rasagiline) for Parkinson's; Xenazine for Huntington's disease; Sabril (vigabatrin) for epilepsy; Rexulti (brexpiprazole) for psychosis and depression; Brintellix/Trintellix (vortioxetine) for depression; and Vyepti (eptinezumab) for migraine. The company markets its products globally, with registrations in over 80 countries, operating through multiple subsidiaries and commercial partners across Europe, North America, and international markets. Founded in 1915 and headquartered in Valby, Denmark, Lundbeck has built a focused innovator strategy centered on neuro-rare and neuro-specialty diseases. In terms of recent major developments, Lundbeck completed the acquisition of Longboard Pharmaceuticals in October 2024 for approximately USD 2.6 billion, adding innovative neurology assets including treatments targeting epilepsy to its portfolio. In 2025, Lundbeck announced strategic commercial partnerships with Swixx Group, Zuellig Pharma, and NewBridge Pharmaceuticals to transition its operations into a partnership model across 27 countries in Europe and international markets. This shift aims to secure continuity of commercial activities while reallocating funds toward investment in high-growth areas and its innovative pipeline. These partnerships enable Lundbeck to focus resources on key growth opportunities while ensuring patient access to its medicines through trusted regional partners, reflecting a broader strategic shift aligning with its long-term growth ambitions in brain health. Lundbeck continues to be a leader in central nervous system pharmaceuticals with a broad and deep portfolio addressing a wide range of neurological and psychiatric conditions.
H. Lundbeck A/S (OTCMKTS:HLUYY) & FIH Mobile (OTCMKTS:FXCNY) Financial Survey
Lundbeck's Appreciation Potential Is Closely Tied To A High-Risk Clinical Pipeline (Rating Upgrade)
Longboard Pharmaceuticals' stock soars amid Lundbeck's $2.6 billion deal to acquire the company
Lundbeck On A Better Path, But With Some Risks
Lundbeck to Present Broad Range of Data on Migraine and Brain Health at 75th Annual Meeting of the American Academy of Neurology
Otsuka Pharmaceutical and Lundbeck to Present Phase 3 Data for Brexpiprazole in Patients with Alzheimer's Dementia at AAIC 2022
H Lundbeck AS (HLUYY) Surges 12.5%: Is This an Indication of Further Gains?
H. Lundbeck A/S (HLUKF) CEO Deborah Dunsire on Q4 2021 Results - Earnings Call Transcript
H. Lundbeck A/S (HLUKF) CEO Deborah Dunsire on Q3 2021 Results - Earnings Call Transcript
H. Lundbeck A/S (HLUKF) CEO Deborah Dunsire on Q2 2021 Results - Earnings Call Transcript